Celia Vidal

Dr. Celia Vidal


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2024 in Respiratory Research
Verified
Journal Article
Open access
PDF file
CVCelia Vidal
Celia Vidal
FBFanny Bertelli
Fanny Bertelli
JMJEAN PIERRE MALLET
JEAN PIERRE MALLET
RGRaphael Gilson
Raphael Gilson
JBJean-Christian Borel
Jean-Christian Borel
DJDany Jaffuel
Dany Jaffuel
Over the past three decades, our understanding of sleep apnea in women has advanced, revealing disparities in pathophysiology, diagnosis, and treatment compared to men. However, no real-life study to date has explored the relationship between mask-related side effects (MRSEs) and gender in the context of long-term CPAP. The InterfaceVent-CPAP study is a prospective real-life cross-sectional study conducted in an apneic adult cohort undergoing at least 3 months of CPAP with unrestricted mask-access (34 different masks, no gender specific mask series). MRSE were assessed by the patient using visual analog scales (VAS). CPAP-non-adherence was defined as a mean CPAP-usage of less than 4 h per day. The primary objective of this ancillary study was to investigate the impact of gender on the prevalence of MRSEs reported by the patient. Secondary analyses assessed the impact of MRSEs on CPAP-usage and CPAP-non-adherence depending on the gender. A total of 1484 patients treated for a median duration of 4.4 years (IQ25–75: 2.0–9.7) were included in the cohort, with women accounting for 27.8%. The prevalence of patient-reported mask injury, defined as a VAS score ≥ 5 (p = 0.021), was higher in women than in men (9.6% versus 5.3%). For nasal pillow masks, the median MRSE VAS score for dry mouth was higher in women (p = 0.039). For oronasal masks, the median MRSE VAS score for runny nose was higher in men (p = 0.039). Multivariable regression analyses revealed that, for both women and men, dry mouth was independently and negatively associated with CPAP-usage, and positively associated with CPAP-non-adherence. In real-life patients treated with long-term CPAP, there are gender differences in patient reported MRSEs. In the context of personalized medicine, these results suggest that the design of future masks should consider these gender differences if masks specifically for women are developed. However, only dry mouth, a side effect not related to mask design, impacts CPAP-usage and non-adherence.

12 July 2025 in Respiratory Research
Verified
Journal Article
Open access
PDF file
CVCelia Vidal
Celia Vidal
JMJEAN PIERRE MALLET
JEAN PIERRE MALLET
SSSarah Skinner
Sarah Skinner
RGRaphael Gilson
Raphael Gilson
OGOlivier Gaubert
Olivier Gaubert
DJDany Jaffuel
Dany Jaffuel
Continuous Positive Airway Pressure (CPAP) telemonitoring is increasingly important in managing obstructive sleep apnea (OSA). The Apnea-Hypopnea Index reported by CPAP devices (AHIflow) is used as a key indicator of treatment effectiveness. However, discrepancies in AHIflow calculation rules between manufacturers may affect clinical decision-making. No prior studies have investigated whether manufacturers’ choices to exclude certain apnea-hypopnea events from the AHIflow calculation may influence the number of patients presenting an AHIflow alert. The aim of this proof-of-concept study was not to compare the manufacturers with each other, but to evaluate, for each manufacturer, how the different possible ways of calculating AHIflow influence the percentage of alert cases. We conducted a retrospective analysis of 13,764 CPAP-treated OSA patients monitored on October 2, 2023. AHIflow calculations were evaluated according to manufacturer-specific rules. When possible, we assessed the impact of excluding central hypopneas, events during major leaks, and/or ramp periods on the percentage of patients crossing the consensual AHIflow alert threshold of ≥ 10 events/h. We identified significant disparities in AHIflow calculations between manufacturers, which lead to significant differences in the number of patients flagged as being in an alert state. Excluding central hypopneas reduced the number of alert cases by 50%, while excluding apneas/hypopneas during major leaks or ramp periods reduced alerts by 20%. Our proof-of-concept study highlights inconsistencies in AHIflow calculations among CPAP manufacturers, raising concerns about patient care. Establishing standardized AHIflow calculation criteria is essential to ensuring accurate monitoring and optimal patient safety.

25 May 2023 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
DJDany Jaffuel
Dany Jaffuel
YBYannick Bouchaut
Yannick Bouchaut
JMJEAN PIERRE MALLET
JEAN PIERRE MALLET
CVCelia Vidal
Celia Vidal
NMNicolas Molinari
Nicolas Molinari
FRFrançois Roubille
François Roubille
Dapagliflozin decreases central sleep apnoea in central sleep apnoea patients, thereby sparing the initiation of ventilatory therapy https://bit.ly/41e2fm0.

28 February 2025 in Sleep and Breathing
Verified
Journal Article
Closed access
PDF file
CVCelia Vidal
Celia Vidal
FBFanny Bertelli
Fanny Bertelli
JMJEAN PIERRE MALLET
JEAN PIERRE MALLET
RGRaphael Gilson
Raphael Gilson
JBJean-Christian Borel
Jean-Christian Borel
DJDany Jaffuel
Dany Jaffuel

11 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CVCelia Vidal
Celia Vidal
JMJEAN PIERRE MALLET
JEAN PIERRE MALLET
SSSarah Skinner
Sarah Skinner
RGRaphael Gilson
Raphael Gilson
OGOlivier Gaubert
Olivier Gaubert
DJDany Jaffuel
Dany Jaffuel
Background: Continuous positive airway pressure (CPAP) effectiveness can be compromised by adverse effects. Despite its potential impact on adherence and sleepiness, aerophagia remains under-recognized and poorly characterized. This ancillary analysis of the InterfaceVent study aimed to identify risk factors for aerophagia in a large real-life cohort of CPAP-treated patients and to assess its association with both CPAP adherence and sleepiness. Methods: InterfaceVent was a prospective, real-life, cross-sectional study. Adults treated for at least 3 months with CPAP were included. Patients self-reported mask-related side effects using visual analogue scales. Aerophagia was defined as a dichotomous outcome based on patient-reported symptoms and CPAP non-adherence as mean nightly usage <4 h. Sleepiness was assessed using Epworth Sleepiness Scale (ESS). Results: A total of 1461 patients (median age 67 years (Q1–Q3; 60–74); 27.6% women) were included. Aerophagia was reported by 8.3% of participants. Compared to patients without aerophagia, those affected were younger, more frequently female, and had lower BMI. Patients with aerophagia reported a median ESS score of 7 (4–10) versus 5 (3–8) for patients without aerophagia (p < 0.001). CPAP usage was significantly lower in the aerophagia group (median 6.37 vs. 6.75 h/day; p = 0.001), whereas non-adherence, did not significantly differ between groups (10.7% vs. 7.5%; p = 0.20). Conclusions: This ancillary analysis of the InterfaceVent study highlights the burden of aerophagia in CPAP-treated patients and identifies modifiable and non-modifiable risk factors. Better recognition and management of this under-reported side effect may improve CPAP adherence and patient comfort. Trial registration: InterfaceVent is registered with ClinicalTrials.gov (NCT03013283). The first registration date is 23 December 2016.

23 January 2025 in Sleep Medicine
Verified
Journal Article
Closed access
CVCelia Vidal
Celia Vidal
JMJEAN PIERRE MALLET
JEAN PIERRE MALLET
SSSarah Skinner
Sarah Skinner
RGRaphael Gilson
Raphael Gilson
OGOlivier Gaubert
Olivier Gaubert
DJDany Jaffuel
Dany Jaffuel